BREAKING
Home » Posts Tagged "TAK-003"

Dengue vaccine candidate: Takeda begins regulatory submissions in the EU and Dengue-endemic countries

By

Takeda Pharmaceutical Company announced recently that the European Medicines Agency (EMA) has accepted the Company’s filing packages for its dengue vaccine candidate (TAK-003) which is being investigated...

Takeda’s Dengue Vaccine Candidate Demonstrates Protection in Children Ages Four to 16 Years, Regardless of Previous Dengue Exposure

By

Takeda Pharmaceutical Company Limited announced that results from the primary endpoint analysis of the ongoing pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial of...

Dengue vaccine candidate proves efficacious in preventing any of the four serotypes of the virus

By

Takeda Pharmaceutical Company Limited today announced that the pivotal Phase 3 trial of its dengue vaccine candidate met the primary efficacy endpoint. This first analysis of the Tetravalent Immunization...

Dengue vaccine candidate: Takeda announces data from 18-month interim Phase 2 trial

By

Takeda Pharmaceutical Company Limited today announced that data from an 18-month interim analysis of the ongoing Phase 2 DEN-204 trial of its live, attenuated tetravalent dengue vaccine candidate, TAK-003...